.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,595,760

« Back to Dashboard
Patent 5,595,760 protects SOMATULINE DEPOT and is included in one NDA.

This patent has sixty-four patent family members in seventeen countries.

Summary for Patent: 5,595,760

Title: Sustained release of peptides from pharmaceutical compositions
Abstract:The invention features a method of administering a peptide to a patient and delivering the peptide continuously over an extended period of time of at least three days by obtaining a solid pharmaceutical composition including a soluble, gelable salt of the peptide and up to 30 percent, by weight, of a pharmaceutically acceptable, soluble, monomeric carrier, and parenterally administering the solid composition to the patient in one injection, wherein the solid composition automatically forms a gel after interaction with the patient's bodily fluids and releases the peptide continuously within the patient over an extended period of at least three days.
Inventor(s): Cherif-Cheikh; Roland (Issy-les-Moulineaux, FR)
Assignee: Delab (Paris, FR)
Application Number:08/400,610
Patent Claim Types:
see list of patent claims
Use; Delivery; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-001Aug 30, 2007RXYes5,595,760► subscribeY METHOD OF ADMINISTERING LANREOTIDE ACETATE
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-002Aug 30, 2007RXYes5,595,760► subscribeY METHOD OF ADMINISTERING LANREOTIDE ACETATE
Ipsen Pharma
SOMATULINE DEPOT
lanreotide acetate
SOLUTION;SUBCUTANEOUS022074-003Aug 30, 2007RXYes5,595,760► subscribeY METHOD OF ADMINISTERING LANREOTIDE ACETATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 5,595,760

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,306,420 Methods and apparatus for the delivery of solid drug compositions► subscribe
5,616,123 Delivery of solid drug compositions► subscribe
5,660,846 Methods and apparatus for the delivery of solid drug compositions► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,595,760

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria188615► subscribe
Austria210424► subscribe
Austria230977► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc